&w=3840&q=100)
Flu shot must as winter viruses may trigger heart attack or stroke: Study
People who are particularly vulnerable to a heart attack or stroke triggered by a respiratory virus are those with more than one of those traditional risk factors, especially older people
The Conversation
Winter is here, along with cold days and the inevitable seasonal surge in respiratory viruses.
But it's not only the sniffles we need to worry about. Heart attacks and strokes also tend to rise during the winter months.
In new research out this week we show one reason why.
Our study shows catching common respiratory viruses raises your short-term risk of a heart attack or stroke. In other words, common viruses, such as those that cause flu and Covid, can trigger them.
Wait, viruses can trigger heart attacks?
Traditional risk factors such as smoking, high cholesterol, high blood pressure, diabetes, obesity and lack of exercise are the main reasons for heart attacks and strokes.
And rates of heart attacks and strokes can rise in winter for a number of reasons. Factors such as low temperature, less physical activity, more time spent indoors – perhaps with indoor air pollutants – can affect blood clotting and worsen the effects of traditional risk factors.
But our new findings build on those from other researchers to show how respiratory viruses can also be a trigger.
The theory is respiratory virus infections set off a heart attack or stroke, rather than directly cause them. If traditional risk factors are like dousing a house in petrol, the viral infection is like the matchstick that ignites the flame.
For healthy, young people, a newer, well-kept house is unlikely to spontaneously combust. But an older or even abandoned house with faulty electric wiring needs just a spark to lead to a blaze.
People who are particularly vulnerable to a heart attack or stroke triggered by a respiratory virus are those with more than one of those traditional risk factors, especially older people.
What we did and what we found
Our team conducted a meta-analysis (a study of existing studies) to see which respiratory viruses play a role in triggering heart attacks and strokes, and the strength of the link. This meant studying more than 11,000 scientific papers, spanning 40 years of research.
Overall, the influenza virus and SARS-CoV-2 (the virus that causes Covid) were the main triggers.
If you catch the flu, we found the risk of a heart attack goes up almost 5.4 times and a stroke by 4.7 times compared with not being infected. The danger zone is short – within the first few days or weeks – and tapers off with time after being infected.
Catching Covid can also trigger heart attacks and strokes, but there haven't been enough studies to say exactly what the increased risk is.
We also found an increased risk of heart attacks or strokes with other viruses, including respiratory syncytial virus (RSV), enterovirus and cytomegalovirus. But the links are not as strong, probably because these viruses are less commonly detected or tested for.
What's going on?
Over a person's lifetime, our bodies wear and tear and the inside wall of our blood vessels becomes rough. Fatty build-ups (plaques) stick easily to these rough areas, inevitably accumulating and causing tight spaces.
Generally, blood can still pass through, and these build-ups don't cause issues. Think of this as dousing the house in petrol, but it's not yet alight.
So how does a viral infection act like a matchstick to ignite the flame? Through a cascading process of inflammation.
High levels of inflammation that follow a viral infection can crack open a plaque. The body activates blood clotting to fix the crack but this clot could inadvertently block a blood vessel completely, causing a heart attack or stroke.
Some studies have found fragments of the Covid virus inside the blood clots that cause heart attacks – further evidence to back our findings.
We don't know whether younger, healthier people are also at increased risk of a heart attack or stroke after infection with a respiratory virus.
That's because people in the studies we analysed were almost always older adults with at least one of those traditional risk factors, so were already vulnerable.
The bad news is we will all be vulnerable eventually, just by getting older.
What can we do about it?
The triggers we identified are mostly preventable by vaccination.
There is good evidence from clinical trials the flu vaccine can reduce the risk of a heart attack or stroke, especially if someone already has heart problems.
We aren't clear exactly how this works. But the theory is that avoiding common infections, or having less severe symptoms, reduces the chances of setting off the inflammatory chain reaction.
Covid vaccination could also indirectly protect against heart attacks and strokes. But the evidence is still emerging.
Heart attacks and strokes are among Australia's biggest killers. If vaccinations could help reduce even a small fraction of people having a heart attack or stroke, this could bring substantial benefit to their lives, the community, our stressed health system and the economy.
What should I do?
At-risk groups should get vaccinated against flu and Covid. Pregnant women, and people over 60 with medical problems, should receive RSV vaccination to reduce their risk of severe disease.
So if you are older or have predisposing medical conditions, check Australia's National Immunisation Program to see if you are eligible for a free vaccine.
For younger people, a healthy lifestyle with regular exercise and balanced diet will set you up for life. Consider checking your heart age (a measure of your risk of heart disease), getting an annual flu vaccine and discuss Covid boosters with your GP.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
37 minutes ago
- Time of India
Lens on new pharmacy colleges in Maharashtra over complaints about forged maps, NOCs, occupancy certificates for approvals
Mumbai: Pharmacy colleges established in the state over the last three years have come under scrutiny following complaints about forged documents, including certified maps and occupation certificates for buildings, being submitted for approvals. More than 115 colleges offering B Pharm and nearly 200 offering D Pharm have emerged during this period. Acting on these complaints, state govt has ordered a re-inspection of all such institutions to verify the authenticity of their documents and whether they meet all the requirements. The aim is to contain the mushrooming of colleges in the state and prevent vacancies of seats during admissions. Data from the Directorate of Technical Education (DTE) shows that over 30% of seats remained vacant last year in both B Pharm and D Pharm courses in the state. In a recent order, govt stated that several complaints were received by the higher and technical education minister regarding pharmacy, diploma, degree, and postgraduate institutions that were granted approval by submitting bogus documents such as certified maps, no-objection certificates (NOCs), occupancy certificates, and utility certificates to state and central govts. The order directed: "The validity of these documents should be verified with the relevant authorities, and an institution-wise inspection report should be submitted to confirm whether adequate educational facilities are available. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Novi ortopedski sandali za moške poletje 2025. Fiippy KUPITE ZDAJ Undo " The Pharmacy Council of India (PCI) gives approval to new institutions once affiliating universities and respective state govts provide them with NOCs. Milind Umekar, president of the Indian Pharmaceutical Congress Association, a federation of five pharmaceutical associations, highlighted two key reasons behind the rapid increase in pharmacy institutions in Maharashtra. "The demand for pharmacy courses surged after the Covid-19 pandemic, as people began recognising growing opportunities in the pharmaceutical industry, including research, clinical studies, pharmacovigilance, formulation and development, and drug or vaccine manufacturing. India ranks third globally in drug production by volume and is among the top exporters. Secondly, before 2022, the PCI imposed a moratorium on setting up new institutes. Once this was lifted following a court order, several colleges rushed to introduce pharmacy programmes," he said, adding that a comprehensive re-inspection exercise is crucial to ensure all institutions meet PCI norms, including the required number of qualified faculty, infrastructure, and laboratories. A representative from a college management said that in the last three years, many colleges were given NOCs by the respective universities, mainly Dr Babasaheb Ambedkar Technological University (BATU) Lonere, without any physical inspection and based on documents submitted by the institutions. "BATU has the highest number of affiliated pharmacy colleges in the state, and most may have come up in the last three years. The university, set up exclusively for technical colleges in the state, faces a severe shortage of manpower, impacting the quality of education in the affiliated institutions," he alleged. A govt official said that officials from the Maharashtra State Board of Technical Education and DTE have started carrying out the inspection exercise, adding that no timeline has been provided.
Time of India
an hour ago
- Time of India
Maharashtra reports 19 new COVID-19 cases
Mumbai: The state recorded 19 new Covid-19 cases on Sunday, taking the state's tally of the viral infections in this calendar year to 2,337, a health department official said. Of the new cases, eight are from Mumbai, six from Pune and its outskirts, two from the limits of the Pimpri Chhinchwad Municipal Corporation near Pune and three from Sangli and nearby areas. No fresh fatality due to coronavirus has been reported in the last four days, an official statement said. The health department said it has conducted 25,519 Covid-19 tests across the state since Jan 1, adding that 2,007 patients have recovered to date. Meanwhile, Mumbai has reported 942 cases, including 509 in June, so far this year. Since Thursday, no deaths due to the viral infection have been reported in the state. A total of 32 patients have succumbed to the virus in the state since January 1, of whom 31 had comorbidities (pre-existing health conditions that can increase the risk of severe illness), the statement said.
Time of India
7 hours ago
- Time of India
A new HIV drug promises 99.9% protection. But it's making Indian health activists wary; Why?
The US Food and Drug Administration (FDA) has approved lenacapavir, a new injectable drug that claims to offer 99.9% protection against HIV. But concerns are being raised in India over its affordability and accessibility, particularly through the public healthcare system. The injection costs around ₹24 lakh ($28,218) for two doses administered six months apart. Lenacapavir belongs to the class of HIV prevention drugs known as pre-exposure prophylaxis (PrEP). However, India's National AIDS Control Organisation (NACO) has not included PrEP in its public programmes so far. "Our govt distributes condoms to break HIV transmission, it provides antiretroviral therapy drugs to prevent parent-to-child transmission of HIV, but it hasn't ever given PrEP to youngsters who are likely to indulge in high-risk behaviour," said health activist Ganesh Acharya. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Hanoi: Unsold Furniture Liquidation 2024 (Prices May Surprise You) Unsold Furniture | Search Ads Learn More Undo He added that NACO had made it mandatory for its counselling centres to provide information on PrEP a couple of years ago. He also expressed concern that 75% of the 88% people diagnosed with HIV in Mumbai in 2023–24 were from the 15–49 age group. PrEP, however, remains available only in the private sector. Experts call for government action, tiered pricing PrEP has existed for over a decade and is widely used in developed countries. In India, public health discussions around PrEP only began recently. Live Events A doctor from a government hospital said, "They set up a committee, then a white paper was brought out that served as a backgrounder for guidelines that were drawn up last year. However, there has been no development since." Dr Ishwar Gilada of the People's Health Organisation (India) said, "The govt should distribute PrEP to check the spread of the disease, which has only been increasing in recent years. The total number of HIV-positive people in India increased from 2.2 million to 2.5 million in a few years." According to him, sexually transmitted infections have been rising in Mumbai. "A recent survey in Mumbai among men who have sex with men found that 60% of them were positive for the human papilloma virus. While gonorrhoea and chlamydia vanished 25 years ago, their numbers are shooting up," he said. He suggested a three-tier pricing structure: full price for those who can afford it, subsidised pricing for some, and free access for those unable to pay. NACO officials were not available for comment. India has also not approved HIV self-testing kits. "We have self-testing kits for pregnancy, diabetes, and Covid, but policymakers fear about the mental health of people after a positive result in self-testing HIV kits," said Dr Gilada. A senior doctor suggested that similar fears may be behind the delay in rolling out PrEP publicly, as officials worry it might encourage risky behaviour. Hope for lower-cost versions as UNAIDS urges price drop Bala from Bombay Gay called lenacapavir a "monumental milestone forward in HIV treatment and prevention," but added that the current price point makes it inaccessible in India. "So, we have to wait and see if prices will come down over time," he said. Dr Gilada expressed hope that Indian manufacturers licensed by Gilead Sciences might eventually offer the injection at less than $100 per year. "India can do it," he said. UNAIDS, in a recent statement, urged Gilead Lifesciences to reduce the price of the new drug to improve global access.
